Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Profound MedicalPROF +1.16%69 3-Year Book Growth Rate is -9.30% as of Mar. 2026. GuruFocus rates PROF with a GF Score™ of 69/100 and a GF Value™ of $14.47 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 761 Medical Devices & Instruments companies, Profound Medical ranks worse than 72.67% on this metric.
During the past 12 months, Profound Medical's average Book Value per Share Growth Rate was -7.50% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -9.30% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -17.30% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 12 years, the highest 3-Year average Book Value per Share Growth Rate of Profound Medical was 46.50% per year. The lowest was -35.10% per year. And the median was -11.40% per year.
Profound Medical (NAS:PROF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Profound Medical 3-Year Book Growth Rate Related Terms
PROF vs ABT, SYK, MDT: 3-Year Book Growth Rate Comparison
For the Medical Devices subindustry, Profound Medical's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical 3-Year Book Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Profound Medical's 3-Year Book Growth Rate falls into.
Profound Medical 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -9.30% mean?
Profound Medical (PROF) has a 3-Year Book Growth Rate of -9.30% as of Mar. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Profound Medical and its competitors. According to the industry distribution chart, Profound Medical ranks #553 out of 761 companies in the Medical Devices & Instruments industry, placing it in the top 72.7%.
Is Profound Medical's 3-Year Book Growth Rate too high?
Profound Medical's current 3-Year Book Growth Rate is -9.30%. Based on the distribution chart, Profound Medical ranks #553 out of 761 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Profound Medical has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's 3-Year Book Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #553 out of 761 companies for 3-Year Book Growth Rate. This places Profound Medical in the lower half of its industry. The industry median 3-Year Book Growth Rate is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Book Growth Rate among Medical Devices & Instruments companies is 2.40, based on 761 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Book Growth Rate is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current 3-Year Book Growth Rate is -9.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.47, compared to a current price of $6.99 — trading 51.7% below its estimated fair value. The current 3-Year Book Growth Rate is -9.30%. Profound Medical's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Profound Medical (PROF), the current 3-Year Book Growth Rate is -9.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $6.99 is trading 51.7% below its estimated GF Value™ of $14.47.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
3-Year Book Growth Rate: -9.30%
GF Value™: $14.47 vs. price of $6.99 (51.7% below fair value)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
69GF Score
Get the complete analysis for PROF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
